Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytotoxic T and natural killer cell cytotoxicities and antitumor immunity

Journal of Gene Medicine

Volumn 5, Issue 8, 2003, Pages 668-680

  Liu, Yongqing ^a   Huang, Hui ^a   Chen, Zhuang ^a   Zong, Li ^a   Xiang, Jim ^a,b  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b Saskatoon Cancer Center   (Canada)

Author keywords

Antitumor immunity; Cytotoxic T lymphocyte; Engineered dendritic cell vaccine; Flt3 ligand; Natural killer cell

Indexed keywords

ADENOVIRUS VECTOR; CANCER VACCINE; DENDRITIC CELL VACCINE; FLT3 LIGAND; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 1; CHEMOKINE; CYTOKINE; FLT3 LIGAND PROTEIN; IMMUNOLOGICAL ADJUVANT; MEMBRANE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CANCER PREVENTION; CELL BASED GENE THERAPY; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFICACY; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; IMMUNOGENICITY; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTECTION; TH1 CELL; TRANSGENE; TUMOR IMMUNITY; UPREGULATION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS RECOMBINANT; ADENOVIRUS; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CELL MOTION; CYTOLOGY; GENETICS; HUMAN; IMMUNE SYSTEM; IMMUNOLOGY; METABOLISM; NATURAL KILLER CELL; NEOPLASM; PHYSIOLOGY; SURVIVAL RATE; T LYMPHOCYTE; TUMOR CELL LINE;

ADENOVIRIDAE; ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; CELL MOVEMENT; CHEMOKINES; CYTOKINES; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNE SYSTEM; KILLER CELLS, NATURAL; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASMS; SURVIVAL RATE; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; TRANSGENES;

EID: 3042609926     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jgm.387     Document Type: Article

References (90)

1. Banchereau J, Steinman R. Dendritic cells and the control of immunity. Nature 1998; 392: 245-252.
2. Steinman R. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991; 9: 271-296.
3. Steinman R, Witmer-Pack M, Inaba K, et al. Dendritic cells: antigen presentation, accessory function and clinical relevance. Adv Exp Med Biol 1993; 329: 1-10.
4. Cella M, Sallusto F, Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol 1997; 9: 10-16.
5. Nestle F, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4: 328-332.
6. Nair S, Snyder D, Rouse B, et al. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Int J Cancer 1997; 70: 706-715.
7. Small D, Levenstein. M, Kim E, et al. STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc Natl Acad Sci 1994; 91: 459-463.
8. Lyman SD, James L, Vanden Bos T, et al. Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor: a proliferative factor for primitive hematopoietic cells. Cell 1993; 75: 1157-1167.
9. Hannum C, Culpepper J, Campbell D, et al. Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs. Nature 1994; 368: 643-648.
10. Rasko JE, Metcalf D, Rossner MT, et al. The flt3/flk-2 ligand: receptor distribution and action on murine haemopoietic cell survival and proliferation. Leukemia 1995; 9: 2058-2066.
11. McKenna HJ, de Vries P, Brasel K, et al. Effect of flt3 ligand on the ex vivo expansion of human CD34+ hematopoietic progenitor cells. Blood 1995; 86: 3413-3420.
12. Curti A, Fogli M, Ratta M, et al. Stem cell factor and Flt3-ligand are strictly required to sustain the long-term expansion of primitive CD34+ DR-dendritic cell precursors. J Immunol 2001; 166: 848-854.
13. Marroquin C, Westwood J, Lapointe R, et al. Mobilization of dendritic cell precursors in patients with cancer by Flt3L allows the generation of higher yields of cultured dendritic cells. J Immunother 2002; 25: 278-288.
14. Maraskovsky E, Brasel K, Teepe M, et al. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J Exp Med 1996; 184: 1953-1962.
15. Pulendran B, Lingappa J, Kennedy M, et al. Developmental pathways of dendritic cells in vivo. Distinct function, phenotype, and localization of dendritic cell subsets in flt3 ligand-treated mice. J Immunol 1997; 159: 2222-2231.
16. Shurin M, Pandharipande P, Zorina T, et al. Flt3 ligand induces the generation of functionally active dendritic cells in mice. Cell Immunol 1997; 179: 174-184.
17. Pulendran B, Smith J, Caspary G, et al. Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. Proc Natl Acad Sci U S A 1999; 96: 1036-1041.
18. Parajuli P, Mosley R, Pisarev V, et al. Flt3 ligand and granulocyte-macrophage colony-stimulating factor preferentially expand and stimulate different dendritic and T-cell subsets. Exp Hematology 2001; 29: 1185-1193.
19. Person J, Esche C, Subbotin V, et al. Flt3L administration inhibits liver metastasis: role of NK cells. J Immunol 1998; 161: 6164-6170.
20. Shaw S, Maung A, Steptoe R, et al. Expansion of functional NK cells in multiple tissue compartments of mice treated with Flt3L: implications for anti-cancer and anti-viral therapy. J Immunol 1998; 161: 2817-2824.
21. Smith J, Thackray A, Bujdoso R. Reduced herpes simplex virus type 1 latency in Flt3L-treated mice is associated with enhanced numbers of natural killer and dendritic cells. Immunology 2001; 102: 352-358.
22. Lynch D, Andreasen A, Maraskovsky E, et al. Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nat Med 1997; 3: 625-631.
23. Esche C, Subbotin V, Maliszewski C, et al. Flt3 ligand administration inhibits tumor growth in murine melanoma and lymphoma. Cancer Res 1998; 58: 380-383.
24. Ciavarra R, Somers K, Brown R, et al. Flt3-ligand induces transient tumor regression in an ectopic treatment model of major histocompatibility complex-negative prostate cancer. Cancer Res 2000; 60: 2081-2084.
25. Chen K, Braun S, Lyman S, et al. Antitumor activity and immunotherapeutic properties of Flt3-ligand in a murine breast cancer model. Cancer Res 1997; 57: 3511-3516.
26. Mach N, Gillessen S, Wilson SB, et al. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand. Cancer Res 2000; 60: 3239-3246.
27. Favre-Felix N, Martin M, Maraskovsky E, et al. Flt3 ligand lessens the growth of tumors obtained after colon cancer cell injection in rats but does not restore tumor-suppressed dendritic cell function. Int J Cancer 2000; 86: 827-834.
28. Sivanandham M, Stavropoulos C, Kim E, et al. Therapeutic effect of colon tumor cells expressing Flt3 ligand plus systemic IL-2 in mice with syngeneic colon cancer. Cancer Immunol Immunother 2002; 51: 63-71.
29. Averbook B, Schuh J, Papay R, et al. Antitumor effects of Flt3L in transplanted murine tumor models. J Immunother 2002; 25: 27-35.
30. Mandelboim O, Berke M, Fridkin M, et al. CTL induction by a tumor-associated antigen octapeptide derived from a murine lung carcinoma. Nature 1994; 369: 67-72.
31. Culpepper H, Campbell D, McClanahan T, et al. Ligand for FLt3/FLK2 regulates growth of haematopoietic stem cells and is encoded by variant RNAs. Nature 1994; 368: 642-648.
32. Wright P, Braun R, Babiuk L, et al. Adenovirus-mediated TNF gene transfer induces significant tumor regression in mice. Cancer Biother Radiopharm 1999; 14: 49-57.
33. Chen Z, Moyana T, Saxena A, et al. Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells. Int J Cancer 2001; 93: 539-548.
34. Xiang J, Moyana T, Qi Y. Genetic engineering of a recombinant fusion protein possessing anti-tumor F(ab)2 and tumor necrosis factor. J Biotechnol 1997; 53: 3-12.
35. Xiang J, Moyana T. Regression of engineered tumor cells secreting cytokines is related to a shift in host cytokine profile from type 2 to type 1. J Interferon Cytokine Res 2000; 20: 349-354.
36. Lentzsch S, Rogers M, LeBlane R, et al. S-3-Amino-phthalimide inhibits angiogenesis and growth of B-cell neoplasias in mice. Cancer Res 2002; 62: 2300-2305.
37. Chen Z, Deham S, Bonham K, et al. DNA array and biological characterization of the impact of the maturation status of mouse dendritic cells on their phenotype and antitumor vaccination efficiency. Cell Immunol 2001; 214: 60-71.
38. Melief C, Kast W. T cell immunotherapy by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes. Immunol Rev 1995; 145: 167-177.
39. Mandelboim O, Vadai E, Fridkin M, et al. Regression of established murine carcinoma metastasis following vaccination with tumor-associated antigen peptides. Nat Med 1995; 1: 1179-1183.
40. Disis ML, Bernhard H, Shiota FM, et al. Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood 1996; 8: 202-210.
41. Gu XG, Schmitt M, Hiasa A, et al. A novel hydrophobized polysaccharide/oncoprotein complex vaccine induces in vitro and in vivo cellular and humoral immune responses against HER2-expressing murine sarcomas. Cancer Res 1998; 58: 3385-3390.
42. Disis M, Gralow J, Bernhard H, et al. Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein. J Immunol 1996; 156: 3151-3158.
43. Disis ML, Grabstein KH, Sleath PR, et al. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res 1999; 5: 1289-1297.
44. + tumors. Cancer Res 1998; 58: 4902-4908.
45. Khutson K. Immunization of cancer patients with HER-2/neu HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. Clin Cancer Res 2002; 8: 1014-1018.
46. Hawkins R, Winter G, Hamblin T, et al. A genetic approach to idiotypic vaccination. J Immunother 1993; 14: 273-278.
47. Chen Y, Hu D, Eling DJ, et al. DNA vaccines encoding full-length or truncated Neu induce protective immunity against Neu-expressing mammary tumors. Cancer Res 1998; 58: 1965-1971.
48. Amici A, Venanzi FM, Concetti A. Genetic immunization against neu/erbB2 transgenic breast cancer. Cancer Immunol Immunother 1998; 47: 183-190.
49. Esserman L, Lopez T, Montes R, et al. Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice. Cancer Immunol Immunother 1999; 47: 337-342.
50. Rovero S, Amici A, Carlo ED, et al. DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol 2000; 165: 5133-5142.
51. Mahon BP, Moore A, Johnson PA, et al. Approaches to new vaccines. Crit Rev Biotechnol 1998; 18: 257-282.
52. Gabrilovich DI, Corak J, Ciernik IF, et al. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res 1997; 3: 483-490.
53. Troy AJ, Summers KL, Davidson PJ, et al. Minimal recruitment and activation of dendritic cells within renal cell carcinoma. Clin Cancer Res 1998; 4: 585-593.
54. Chaux P, Favre N, Martin M, et al. Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression in rats. Int J Cancer 1997; 72: 619-624.
55. Dhodapkar MV, Steinman RM, Sapp M, et al. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J Clin Invest 1999; 104: 173-180.
56. Toes R, van der Voort E, Schoenberger S, et al. Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells. J Immunol 1998; 160: 4449-4458.
57. Schreurs M, Eggert A, de Boer A, et al. DCs break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model. Cancer Res 2000; 60: 6995-7001.
58. Bellone M, Cantarella D, Castiglioni P, et al. Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma. J Immunol 2000; 165: 2651-2656.
59. Parra E, Wingren A. Hedlund G, et al. The role of B7-1 and LFA-3 in costimulation of CD8 T cells. J Immunol 1997; 158 637-642.
60. Gabrilovech D, Chen H. Girgis K, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996; 2: 1096-1103.
61. Miller P, Sharma S, Stolina M, et al. Dendritic cells augment granulocyte-macrophage colony-stimulating factor (GM-CSF)/herpes simplex virus thymidine kinase-mediated gene therapy of lung cancer. Cancer Gene Ther 1998; 5: 380-389.
62. Miller P, Sharma S, Stolina M, et al. Intratumoral administration of adenoviral interleukin-7 gene-modified dendritic cells augments specific antitumor immunity and achieves tumor eradication. Hum Gene Ther 2000; 11: 53-65.
63. Turing T, Wilson C, Martin D, et al. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-γ. J Immunol 1998; 160: 1139-1147.
64. Nishioka Y, Hirao M, Robbins P. et al. Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12. Cancer Res 1999; 59: 4035-4041.
65. Caux C, Dezutter D, Schmitt D, et al. GM-CSF and TNF cooperate in the generation of dendritic Langerhans cells. Nature 1992; 360: 258-262.
66. Romani N, Gruner E, Brang A, et al. Proliferating dendritic cell progenitors in human blood. J Exp Med 1994; 180 83-89.
67. Zhou L, Tedder T. CD14+ blood monocytes can differentiate into functional mature CD83+ dendritic cells. Proc Natl Acad Sci USA 1996; 93: 2588-2593.
68. Disis M, Bernhard F, Shiota F, et al. Granulocyte-macrophage-colony stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood 1996; 88: 202-212.
69. Jager E, Ringhoffer H, Dienes H, et al. GM-CSF enhances immune responses to melanoma-associated peptides in vivo. Int J Cancer 1996; 67: 54-64.
70. Curiel-Lewandrowski C, Mahnke K, Labeur M, et al. Transfection of immature murine bone marrow-derived dendritic cells with the granulocyte-macrophage colony-stimulating factor gene potently enhances their in vivo antigen-presenting capacity. J Immunol 1999; 163: 174-183.
71. Pulendran B, Banchereau J, Burkeholder S, et al. Flt3L and GM-CSF mobilize distinct human dendritic cell subsets in vivo. J Immunol 2000; 165: 566-572.
72. Zhong L, Granelli-Piperno A, Choi Y, et al. Recombinant adenovirus is an efficient and non-perturbing genetic vector for human dendritic cells. Eur J Immunol 1999; 29: 964-972.
73. Tillman B, de Gruijl T, Luykx-de Bakker S, et al. Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenovirus vector. J Immunol 1999; 162: 6378-6383.
74. Dietz A, Bulur P, Brown C, et al. Maturation of dendritic cells infected by recombinant adenovirus can be delayed without impact in transgene expression. Gene Ther 2001; 8: 419-423.
75. Hirschowitz E, Weaver J, Hidalgo G, et al. Murine dendritic cells infected with adenovirus vectors show signs of activation. Gene Ther 2000; 7: 1112-1120.
76. Lyakh L, Koski G, Young H, et al. Adenovirus type 5 vectors induce dendritic cell differentiation in human CD14 monocytes cultured under serum-free conditions. Blood 2002; 99: 600-608.
77. Liu Y, Zhang X, Zhang W, et al. Adenovirus-mediated CD40 ligand gene-engineered dendritic cells elicit enhanced CD8 cytotoxic T-cell activation and antitumor immunity. Cancer Gene Ther 2002; 9: 202-208.
78. Hart D. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 1997; 90: 3245-3287.
79. Sozzani S, Locati M, Allavena P, et al. Chemokines: a superfamily of chemotactic cytokines. Int J Clin Lab Res 1996; 26: 69-82.
80. Liu Y, Huang H, Saxena A, et al. Intratumoral coinjection of two adenoviral vectors expressing functional IL-18 and IP-10, respectively, synergizes to facilitate regression of established tumors. Cancer Gene Ther 2002; 9: 533-542.
81. Wolpe S, Cerami A. Macrophage inflammatory proteins 1 and 2: members of a novel superfamily of cytokines. FASEB J 1989; 3: 2565-2573.
82. Parajuli P, Pisarev V, Sublet J, et al. Immunization with wild-type p53 gene sequences coadministered with Flt3 ligand induces an antigen-specific type 1 T-cell response. Cancer Res 2001; 61 8227-8234.
83. Talmadge J, Meyers K, Prieur D, et al. Role of natural killer cells in tumor growth and metastasis: C57BL/6 normal and beige mice. Nature 1980; 284: 622-625.
84. Trinchieri G. Biology of natural killer cells. Adv Immunol 1989; 47: 187-303.
85. Chambers W, Brissette-Strorkus C. Hanging in the balance: natural killer cell recognition of target cells. Chem Biol 1995; 2: 429-435.
86. Lanier L, Phillips J. Inhibitory MHC class I receptors on NK and T cells. Immunol Today 1996; 17: 86-91.
87. Lanier L. Follow the leader: NK cell receptors for classical and nonclassical MHC class I. Cell 1998; 92: 705-707.
88. Karre K, Ljunggren H, Piontek G, et al. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defense strategy. Nature 1986; 319: 675-678.
89. Fernandez N, Lozier A, Flament C, et al. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med 1999; 5: 405-411.
90. Labeur M, Roters B, Pers B, et al. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. J Immunol 1999; 162: 168-175.